Enzymotec Securities Litigation

Welcome to the settlement website for the Enzymotec Securities Litigation (the “Litigation”).

The purpose of this website is to inform you of the Settlement of the Litigation and of the hearing held by the Court to consider the fairness, reasonableness, and adequacy of the Settlement, as well as counsel’s application for fees, costs, and expenses. The Notice explains the lawsuit, the Settlement, your legal rights, what benefits were available, and who was eligible for them.

The Settlement resolves claims by members of the Class, i.e., all persons or entities who purchased or otherwise acquired the common stock of Enzymotec (ticker symbol: ENZY) between September 27, 2013 and August 4, 2014, inclusive, and were damaged thereby, and/or purchased shares of Enzymotec common stock issued in the Initial Public Offering that occurred on or about September 27, 2013, and were damaged thereby, and/or purchased shares of Enzymotec common stock issued in the Secondary Public Offering that occurred on or about February 27, 2014, and were damaged thereby.

If you are a member of the Class, your legal rights are affected whether you act or do not act.

The Court held a Final Approval Hearing on January 24, 2018 at 10:30 a.m.

On August 16, 2019, the Court approved a distribution to eligible claimants and payments were issued on October 15, 2019. If you have questions about your payment, please contact the Claims Administrator at 1-844-418-6627.